Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Arch Biopartners Inc

ARCH
1,89
0,00 (0,00%)
07 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: TSX Venture
Tipo: Azione
Valuta: CAD

Ultime notizie

Data Ora Fonte Titolo
03/2/202513:45GLOBEShares for Interest Debt Settlement
08/1/202513:25GLOBEArch Biopartners Announces Ontario Research Ethics Board..
11/11/202419:46APSDosing of First Patient in a Trial for LSALT Peptide is..
11/11/202413:30GLOBEArch Biopartners Announces Dosing of First Patient in Canada..
16/10/202400:23GLOBEArch Biopartners Arranges Non-Brokered Private Placement
03/10/202413:45GLOBECloses Units for Debt Settlement
26/9/202414:46GLOBEUnits for Debt Settlement
11/9/202412:30GLOBEArch Biopartners Announces Alberta Health Services Approval..
02/8/202413:20GLOBEArch Biopartners’ Cilastatin Drug Candidate to Participate..
30/7/202422:47GLOBEArch Biopartners Closes Non-Brokered Private Placement
29/7/202422:52GLOBEArch Biopartners Arranges Non-Brokered Private Placement
27/6/202413:25GLOBEArch Biopartners Announces GMP Manufacturing of Cilastatin..
18/6/202413:35GLOBEArch Biopartners Announces University of Calgary Ethics..
16/4/202413:14GLOBESt. Michael’s Hospital Joins the Phase II Trial of LSALT..
03/4/202413:00GLOBEUHN Joins the Phase II Trial of LSALT Peptide Targeting..
02/4/202413:26GLOBEArch Biopartners Adds Three New Clinical Sites into the..
18/3/202412:28GLOBEArch Biopartners Clinical Team Publishes Data from Phase II..
15/3/202412:05GLOBEUniversity of Calgary Joins the Phase II Trial of LSALT..
07/3/202413:26GLOBEArch Biopartners Announces Dosing of First Patient in Phase..
27/2/202413:25GLOBEArch Biopartners Has Pre-IND Meeting With FDA to Discuss..
Apertura: 1,90 Min: 1,86 Max: 1,90
Chiusura: 1,89

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network